GlassScriptPhysician profile
Kathy M Clewell
NPI 1326100835
$13,104.90
in general payments reported to CMS, 2019-2025
43 companies · $5,858 in 2025
The $5,858 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $433 · 2021: $935 · 2022: $2,808 · 2023: $917 · 2024: $1,194 · 2025: $5,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,050 · Food and Beverage: $3,514 · Travel and Lodging: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,050.00 |
| Food and Beverage | $3,513.93 |
| Travel and Lodging | $404.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,118.93 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $1,956.86 | 2022 | |
| Glaxosmithkline, LLC. | $865.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $587.94 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $542.78 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $470.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $414.13 | 2019-2025 | Wegovy, Ozempic |
| Kowa Pharmaceuticals America, INC. | $357.19 | 2019-2022 | |
| Pfizer INC. | $297.65 | 2020-2025 | |
| Radius Health, INC. | $281.05 | 2019-2025 | Tymlos |
| Esperion Therapeutics, INC. | $280.08 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $220.81 | 2019-2022 | |
| Eisai INC. | $207.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.25 | 2022-2025 | |
| Seqirus USA INC | $130.20 | 2022-2025 | Flucelvax, Fluad |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Clewell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.